Profound Medical (PROF) to Announce Quarterly Earnings on Thursday

by · The Cerbat Gem

Profound Medical (NASDAQ:PROF – Get Free Report) is anticipated to issue its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect Profound Medical to post earnings of ($0.22) per share and revenue of $4.75 million for the quarter. Interested persons may review the information on the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:30 PM ET.

Profound Medical (NASDAQ:PROF – Get Free Report) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.19) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.05. The business had revenue of $5.34 million during the quarter, compared to the consensus estimate of $4.85 million. Profound Medical had a negative return on equity of 78.88% and a negative net margin of 206.76%. On average, analysts expect Profound Medical to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Profound Medical Trading Up 2.9%

PROF stock traded up $0.23 during trading hours on Tuesday, hitting $8.47. 61,883 shares of the stock were exchanged, compared to its average volume of 158,110. Profound Medical has a 12 month low of $3.76 and a 12 month high of $8.95. The firm has a market capitalization of $307.98 million, a P/E ratio of -6.83 and a beta of 0.73. The company has a 50-day simple moving average of $6.90 and a two-hundred day simple moving average of $6.80.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on PROF. Weiss Ratings upgraded shares of Profound Medical from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, July 29th. Raymond James Financial raised shares of Profound Medical from an “outperform” rating to a “strong-buy” rating and set a $11.00 target price on the stock in a report on Monday, July 27th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $11.50.

Get Our Latest Research Report on Profound Medical

Institutional Investors Weigh In On Profound Medical

Large investors have recently bought and sold shares of the company. Alyeska Investment Group L.P. bought a new position in Profound Medical in the fourth quarter valued at about $5,340,000. Rosalind Advisors Inc. lifted its holdings in shares of Profound Medical by 54.4% in the fourth quarter. Rosalind Advisors Inc. now owns 1,068,955 shares of the company’s stock worth $8,413,000 after acquiring an additional 376,770 shares during the last quarter. FIL Ltd lifted its holdings in shares of Profound Medical by 16.7% in the fourth quarter. FIL Ltd now owns 2,200,000 shares of the company’s stock worth $17,270,000 after acquiring an additional 315,000 shares during the last quarter. Essex Investment Management Co. LLC acquired a new stake in shares of Profound Medical in the 4th quarter valued at approximately $2,437,000. Finally, Velan Capital Investment Management LP acquired a new stake in shares of Profound Medical in the 4th quarter valued at approximately $2,249,000. 47.86% of the stock is currently owned by institutional investors and hedge funds.

Profound Medical Company Profile

(Get Free Report)

Profound Medical Corp is a medical technology company headquartered in Toronto, Canada, that specializes in the development and commercialization of minimally invasive therapeutic solutions using magnetic resonance–guided ultrasound ablation. The company’s proprietary platform delivers focused ultrasound energy to targeted tissue under real-time MR imaging, offering a non-incisional alternative to traditional surgical approaches.

The company’s lead product, the TULSA-PRO system, is designed for the treatment of prostate conditions, including localized prostate cancer and benign prostatic hyperplasia.

Featured Stories